Dr. Maria Colavincenzo, MD

Dr. Colavincenzo practices at Northwestern Medicine Dialysis Center in Chicago, Illinois.

Dr. Colavincenzo's NPI, 1598931719, was assigned on May 7, 2008. Dr. Colavincenzo graduated from Perelman School of Med at the University of Pennsylvania in 2004. Dr. Colavincenzo holds Illinois license 036.123111.

Dr. Colavincenzo's primary practice is Northwestern Medicine Dialysis Center, at 676 N St Clair St 20th Fl Ste 2020, Chicago, IL 60611 in Cook County. The practice phone is (312) 472-5200.

Dr. Colavincenzo's primary practice is Northwestern Medicine Dialysis Center in Chicago, Illinois. Dr. Colavincenzo is also affiliated with Northwestern Memorial Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Colavincenzo to 1 more group practice or clinic, named with a free account. Dr. Colavincenzo's employer is on file too: a dialysis center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Colavincenzo practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Colavincenzo's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Colavincenzo is licensed in Illinois.

CMS data shows 1,163 Medicare services from Dr. Colavincenzo across 14 procedure codes in 2024, for 479 Medicare patients. Medicare paid $77,331 for them. Every service was in an office.

CMS counts 479 Medicare patients who saw Dr. Colavincenzo in 2024. The largest group is 65 to 74, with 230 patients. 75% of them have high cholesterol, and 50% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.00, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Colavincenzo's median patient age at 61, with 74% women.

In 2024, Dr. Colavincenzo wrote 2,057 Medicare Part D claims for 428 patients. 94% of them were for generic drugs. CMS names the drug for 1,930 of them, across 24 drugs with 11 or more claims each, at $220,776 in total drug cost. In 2023, CMS named 1,624 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Colavincenzo for performance year 2024, reported through an alternative payment model (APM). Dr. Colavincenzo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 164 procedures of removal of skin lesions by Dr. Colavincenzo, more than 78% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links Dr. Colavincenzo to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Alopecia Areata, Bronchiolitis Obliterans Syndrome and Alopecia. Open Payments lists research payments to Dr. Colavincenzo that name 1 trial.

CMS Open Payments shows 9 general payments to Dr. Colavincenzo from 4 drug and device companies from 2018 to 2025. Travel and lodging make up the largest share, 61% of the total. Eli Lilly and Company paid the most, $1,192. It also lists 4 research payments totaling $845 from 2020 to 2023, naming 1 clinical trial.

Dr. Colavincenzo graduated from Perelman School of Med at the University of Pennsylvania in 2004.